Synactix Pharmaceuticals, Inc. is taking a different path towards addressing cancer as a whole. Synactix is focused to identifying specific malignant pathways in particular cancers that are amenable to therapeutic intervention. Using bioinformatics, pathways that are interdependent are identified and a single-agent is created that can block both pathways at the same therapeutic dose. Synactix has invented an effective strategy to block multiple, malignant pathways to decrease the frequency of resistant disease - practicing precision medicine through the strategic targeting of multiple-disease pathways with a single-agent.
